Human ES-derived MSCs correct TNF-α-mediated alterations in a blood–brain barrier model
2019
Background
Immune cell trafficking into the CNS is considered to contribute to pathogenesis in MS and its animal model, EAE. Disruption of the blood–brain barrier (BBB) is a hallmark of these pathologies and a potential target of therapeutics. Human embryonic stem cell-derived mesenchymal stem/stromal cells (hES-MSCs) have shown superior therapeutic efficacy, compared to bone marrow-derived MSCs, in reducing clinical symptoms and neuropathology of EAE. However, it has not yet been reported whether hES-MSCs inhibit and/or repair the BBB damage associated with neuroinflammation that accompanies EAE.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
151
References
5
Citations
NaN
KQI